Developer docs
API playgroundTry for free, no card

Search company profiles

Bryleos

Full company profile

uuid0000nfs

Namestring
Bryleos
Legal namestring
BioNADrx Holdings, Inc.
Websiteurl
bryleos.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Bryleos is a clinical-stage therapeutics company developing interventions for neurological diseases of aging by leveraging NAD+ biology. Its lead asset, BRY101 (also referenced as BNAD101), is described as a first-in-class oral therapeutic designed to modulate multiple hallmarks of aging simultaneously — specifically mitochondrial dysfunction, neuroinflammation, and oxidative stress — rather than acting on a single target. The initial indication set spans neurodegenerative conditions including Alzheimer's, Parkinson's, ALS, Multiple Sclerosis, and FSHD, with a secondary indication in substance use disorder supported by a proof-of-concept study at the Institute for Systems Biology showing a 52% increase in intracellular NAD+ levels within five days.

The company's underlying technology comprises two layers: (1) an AI and machine learning-enabled drug discovery platform positioned to accelerate target identification and development timelines, and (2) the proprietary LathMized™ Green Platform Technology, a manufacturing/process platform that optimizes the bioavailability and stability of molecular entities using waterless, low-energy, and non-toxic processes. Bryleos is privately held, headquartered in Johnson City, Tennessee (legal entity BioNADrx Holdings, Inc.), was founded in 2021, operates with 1–10 employees, and has raised $5 million in seed funding in June 2023 with Eddie Jordan among the backers.

Bryleos is pre-revenue with no approved product, no pricing model, and no disclosed customers. Its business model is the standard clinical-stage therapeutics pathway: develop BRY101 through preclinical and clinical milestones toward regulatory approval, with future commercialization through traditional pharmaceutical distribution (healthcare provider prescriptions and pharmacy dispensing) in the United States. The LathMized™ platform carries optionality for broader application to existing drugs and supplements, but no licensing or partnership revenue has been disclosed to date. The company's GTM motion is therefore entirely upstream — research partnerships, investigator relationships, and investor communications via LinkedIn and the corporate website — until regulatory milestones unlock commercialization.

Short descriptiontext

Bryleos is a pre-revenue, clinical-stage therapeutics company developing BRY101, a first-in-class oral NAD+ therapeutic for neurodegenerative diseases of aging and substance use disorder, using its proprietary LathMized™ Green Platform Technology and AI/ML-driven drug discovery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersJohnson City, United States
HQ citystring
Johnson City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative therapeutics, NAD+ drug development, green pharma technology, oral small molecule drugs, mitochondrial dysfunction therapy
Industry1 code
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Chemical Manufacturing325
  • Other Basic Organic Chemical Manufacturing32519
  • Environmental Consulting Services541620
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-stage Neurodegenerative Therapeutics
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bryleos is a clinical-stage biopharmaceutical company developing BRY101, a first-in-class oral therapeutic that targets mitochondrial dysfunction, neuroinflammation, and oxidative stress to treat neurodegenerative diseases of aging (Alzheimer's, Parkinson's, ALS, Multiple Sclerosis, FSHD) and substance use disorder. The program is supported by the proprietary LathMized™ Green Platform Technology, which optimizes bioavailability and stability of molecular entities through sustainable, waterless, low-energy manufacturing processes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 52% increase in intracellular NAD levels within 5 days
Product overview1 text field

Bryleos is developing interventions for neurological diseases of aging by leveraging NAD+ therapeutics and advanced technology. The company's lead product is BRY101, a first-in-class oral therapeutic targeting multiple hallmarks of aging including mitochondrial dysfunction, neuroinflammation, and oxidative stress. This is supported by the LathMized™ Green Platform Technology, which optimizes bioavailability and stability of therapeutic compounds using sustainable, waterless processes.

Product and service1 record
1BRY101
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-13
Description

Conducted the proof-of-concept study for BNAD101 showing a 52% increase in intracellular NAD levels within 5 days. Study supports the potential of BNAD101 to treat conditions requiring rapid response, such as addiction.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Consumer and clinical-stage company built around NAD+ biology and aging biology, developing both supplement and therapeutic NAD+-boosting products — directly comparable mechanism and indication overlap to Bryleos' BRY101.

2Metro International Biotech
TypeDirect peer
Description

Clinical-stage developer of NAD+ precursor therapeutics (e.g., MIB-626) for aging-related and metabolic indications; closest direct mechanistic peer to Bryleos' NAD+ restoration approach.

3ChromaDex
TypeDirect peer
Description

Markets nicotinamide riboside (Niagen) and other NAD+ precursors for consumer health and pharma partnerships; comparable NAD+ mechanism and platform-extension commercial model.

TypeDirect peer
Description

Clinical-stage biotech developing orally delivered small molecules for neurodegenerative diseases (Alzheimer's, Parkinson's), sharing target indications and small-cap clinical-stage profile with Bryleos.

TypeDirect peer
Description

Commercial/clinical-stage developer of therapeutics for neurodegenerative diseases (ALS, Alzheimer's); directly comparable indication focus and CNS drug-development trajectory.

6Cassava Sciences
TypeDirect peer
Description

Clinical-stage CNS company developing treatments for Alzheimer's disease; comparable small-cap, single-asset neurodegeneration profile to Bryleos.

TypeDirect peer
Description

Clinical-stage biotech focused on neurodegeneration and lysosomal biology, with multiple CNS programs; comparable indication focus though at significantly larger scale.

TypeDirect peer
Description

Clinical-stage CNS-focused biotech pursuing novel mechanisms for neurological diseases; comparable small-cap, mechanism-driven CNS development profile.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics that target the biology of aging, including neurodegeneration; directly comparable hallmarks-of-aging therapeutic thesis.

TypeEmerging player
Description

Early clinical-stage biotech leveraging AI/ML for neuroscience drug discovery with focus on Parkinson's and other neurodegenerative diseases — overlaps Bryleos on both indication and AI-driven discovery approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bryleos

Clinical-stage Neurodegenerative Therapeuticsbryleos.com

Bryleos is a pre-revenue, clinical-stage therapeutics company developing BRY101, a first-in-class oral NAD+ therapeutic for neurodegenerative diseases of aging and substance use disorder, using its proprietary LathMized™ Green Platform Technology and AI/ML-driven drug discovery.

What Bryleos does

Bryleos is a clinical-stage therapeutics company developing interventions for neurological diseases of aging by leveraging NAD+ biology. Its lead asset, BRY101 (also referenced as BNAD101), is described as a first-in-class oral therapeutic designed to modulate multiple hallmarks of aging simultaneously — specifically mitochondrial dysfunction, neuroinflammation, and oxidative stress — rather than acting on a single target. The initial indication set spans neurodegenerative conditions including Alzheimer's, Parkinson's, ALS, Multiple Sclerosis, and FSHD, with a secondary indication in substance use disorder supported by a proof-of-concept study at the Institute for Systems Biology showing a 52% increase in intracellular NAD+ levels within five days.

The company's underlying technology comprises two layers: (1) an AI and machine learning-enabled drug discovery platform positioned to accelerate target identification and development timelines, and (2) the proprietary LathMized™ Green Platform Technology, a manufacturing/process platform that optimizes the bioavailability and stability of molecular entities using waterless, low-energy, and non-toxic processes. Bryleos is privately held, headquartered in Johnson City, Tennessee (legal entity BioNADrx Holdings, Inc.), was founded in 2021, operates with 1–10 employees, and has raised $5 million in seed funding in June 2023 with Eddie Jordan among the backers.

Bryleos is pre-revenue with no approved product, no pricing model, and no disclosed customers. Its business model is the standard clinical-stage therapeutics pathway: develop BRY101 through preclinical and clinical milestones toward regulatory approval, with future commercialization through traditional pharmaceutical distribution (healthcare provider prescriptions and pharmacy dispensing) in the United States. The LathMized™ platform carries optionality for broader application to existing drugs and supplements, but no licensing or partnership revenue has been disclosed to date. The company's GTM motion is therefore entirely upstream — research partnerships, investigator relationships, and investor communications via LinkedIn and the corporate website — until regulatory milestones unlock commercialization.

Bryleos firmographics

Firmographics
Name
Bryleos
Legal name
BioNADrx Holdings, Inc.
Website
https://bryleos.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Bryleos is a pre-revenue, clinical-stage therapeutics company developing BRY101, a first-in-class oral NAD+ therapeutic for neurodegenerative diseases of aging and substance use disorder, using its proprietary LathMized™ Green Platform Technology and AI/ML-driven drug discovery.
Ownership category
akta.pro rank

Bryleos industry classification

Industry
Product category
Clinical-stage Neurodegenerative Therapeutics
NAICS
Chemical Manufacturing (325), Other Basic Organic Chemical Manufacturing (32519), Environmental Consulting Services (541620)
SIC
Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neurodegenerative therapeutics
  • NAD+ drug development
  • Green pharma technology
  • Oral small molecule drugs
  • Mitochondrial dysfunction therapy

Where Bryleos is headquartered

Location

Headquarters

HQ city
Johnson City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Bryleos business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Marketing channels1 record

Bryleos product offering

Product offering

Core offering

Bryleos is a clinical-stage biopharmaceutical company developing BRY101, a first-in-class oral therapeutic that targets mitochondrial dysfunction, neuroinflammation, and oxidative stress to treat neurodegenerative diseases of aging (Alzheimer's, Parkinson's, ALS, Multiple Sclerosis, FSHD) and substance use disorder. The program is supported by the proprietary LathMized™ Green Platform Technology, which optimizes bioavailability and stability of molecular entities through sustainable, waterless, low-energy manufacturing processes.

Product overview

Bryleos is developing interventions for neurological diseases of aging by leveraging NAD+ therapeutics and advanced technology. The company's lead product is BRY101, a first-in-class oral therapeutic targeting multiple hallmarks of aging including mitochondrial dysfunction, neuroinflammation, and oxidative stress. This is supported by the LathMized™ Green Platform Technology, which optimizes bioavailability and stability of therapeutic compounds using sustainable, waterless processes.

Differentiator

Problem solved

Functional benefit

Products and services

  • BRY101

Quantifiable outcome

  • 52% increase in intracellular NAD levels within 5 days

Companies that use Bryleos

Customer profile

Segments2 records

Ideal customer profiles2 records

Bryleos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Bryleos partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Institute for Systems BiologycoreStrategic or Co-development Partner · 13 June 2023Conducted the proof-of-concept study for BNAD101 showing a 52% increase in intracellular NAD levels within 5 days. Study supports the potential of BNAD101 to treat conditions requiring rapid response, such as addiction.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Bryleos competitors and assessment

Company assessment

Direct peers

  • Elysium Health: Consumer and clinical-stage company built around NAD+ biology and aging biology, developing both supplement and therapeutic NAD+-boosting products — directly comparable mechanism and indication overlap to Bryleos' BRY101.
  • Metro International Biotech: Clinical-stage developer of NAD+ precursor therapeutics (e.g., MIB-626) for aging-related and metabolic indications; closest direct mechanistic peer to Bryleos' NAD+ restoration approach.
  • ChromaDex: Markets nicotinamide riboside (Niagen) and other NAD+ precursors for consumer health and pharma partnerships; comparable NAD+ mechanism and platform-extension commercial model.
  • Annovis Bio: Clinical-stage biotech developing orally delivered small molecules for neurodegenerative diseases (Alzheimer's, Parkinson's), sharing target indications and small-cap clinical-stage profile with Bryleos.
  • Amylyx Pharmaceuticals: Commercial/clinical-stage developer of therapeutics for neurodegenerative diseases (ALS, Alzheimer's); directly comparable indication focus and CNS drug-development trajectory.
  • Cassava Sciences: Clinical-stage CNS company developing treatments for Alzheimer's disease; comparable small-cap, single-asset neurodegeneration profile to Bryleos.
  • Denali Therapeutics: Clinical-stage biotech focused on neurodegeneration and lysosomal biology, with multiple CNS programs; comparable indication focus though at significantly larger scale.
  • Cyclerion Therapeutics: Clinical-stage CNS-focused biotech pursuing novel mechanisms for neurological diseases; comparable small-cap, mechanism-driven CNS development profile.
  • BioAge Labs: Clinical-stage biotech developing therapeutics that target the biology of aging, including neurodegeneration; directly comparable hallmarks-of-aging therapeutic thesis.

Emerging players

  • Neuron23: Early clinical-stage biotech leveraging AI/ML for neuroscience drug discovery with focus on Parkinson's and other neurodegenerative diseases — overlaps Bryleos on both indication and AI-driven discovery approach.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Bryleos social profiles

Digital presence

Bryleos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bryleos leadership team

Management profile

Number of profiles

Profiles1 record

Bryleos funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bryleos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bryleos

What does Bryleos do?

Bryleos is a clinical-stage biopharmaceutical company developing BRY101, a first-in-class oral therapeutic that targets mitochondrial dysfunction, neuroinflammation, and oxidative stress to treat neurodegenerative diseases of aging (Alzheimer's, Parkinson's, ALS, Multiple Sclerosis, FSHD) and substance use disorder. The program is supported by the proprietary LathMized™ Green Platform Technology, which optimizes bioavailability and stability of molecular entities through sustainable, waterless, low-energy manufacturing processes.

Is Bryleos a public or private company?

Bryleos is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bryleos founded?

Bryleos was founded in 2021. It employs 1 to 10 people.

Where is Bryleos based?

Bryleos is headquartered in Johnson City, United States, in the North America region.

Who are Bryleos's main competitors?

Direct peers on record are Elysium Health, Metro International Biotech, ChromaDex, Annovis Bio, Amylyx Pharmaceuticals, Cassava Sciences, Denali Therapeutics, Cyclerion Therapeutics and BioAge Labs. Neuron23 is listed as an emerging player.

Does Bryleos have an API?

No public API is recorded for Bryleos.

What industry is Bryleos in?

Bryleos's product category is Clinical-stage Neurodegenerative Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileApptly's UberDoc Partners with Bryleos, Bringing Woman-Owned Cellular-Health Innovator onto the MarketplaceApptly Health Technologies Corp., operator of the UberDoc direct-pay healthcare marketplace, announced a strategic partnership with Bryleos (BioNADrx Holdings, Inc.), a woman-owned life sciences company focused on NAD+ science and cellular health formulations. Through this partnership, Bryleos gains a dedicated presence on the UberDoc marketplace, providing patients and physicians direct access to its patent-pending LathMized® NAD+ platform and science-backed cellular health offerings. The announcement marks another step in Apptly's platform strategy to expand beyond specialist care and build multiple revenue streams across its ecosystem.Stock TitanApptly Partners With Bryleos on NAD+ MarketplaceApptly Health Technologies Corp., operator of the UberDoc direct-pay healthcare marketplace, announced a strategic partnership with Bryleos (BioNADrx Holdings, Inc.), a woman-owned life sciences company focused on NAD+ science and oral cellular-health formulations. Bryleos joins the UberDoc marketplace with a dedicated company presence, providing patients and physicians direct access to its patent-pending LathMized® NAD+ platform backed by peer-reviewed research. The partnership extends UberDoc's platform ecosystem beyond specialist care as Apptly builds toward multiple revenue streams.ForbesMedical Breakthrough Offers Hope To Those Fighting AddictionBryleos, led by Wendy Komac, completed a proof-of-concept trial for an oral NAD+ drug that reduces withdrawal symptoms from opioids and alcohol within five days. The company raised $5 million to bring the treatment to market. Komac plans a Phase One study after filing an IND with the FDA.FinSMEsBryleos Raises $5M in Seed FundingBryleos, a clinical stage therapeutics company based in Nashville, raised $5 million in seed funding. The capital will be used to develop BNAD101, a novel oral composition of NAD+ currently in clinical trials. Notable backers include early investor Eddie Jordan.EIN PresswireBryleos secures $5M to develop a treatment for substance use disorder, and announces breakthrough BNAD101 study resultsBryleos secured a $5 million seed round to develop BNAD101, a novel oral composition of NAD+ for treating substance use disorder. The company simultaneously announced initial results from its Phase 1 Proof-of-Concept trial, which demonstrated a 52% increase in intracellular NAD levels within five days among healthy adults.